Stoke Therapeutics, Inc. (STOK) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
the bull case· 4
199
managers reporting a position in thirteen f filings
13fJun 30 '26+1.25%
change in shares held by the ten largest reporting managers
13fJun 30 '263
disclosed supplier and customer ties in sec filings
sec filingsedgar4
of the funds on file reporting a position in stok
n-portas of Jun 30 '26the bear case· 4
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized6 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2621
managers whose positions together make up four fifths of the reported value
13fJun 30 '260.48%
of State Street SPDR S and P Biotech ETF assets as largest fund weight
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
198 managers report a position worth $2.5B between them, and 21 of them hold 80% of it.
Of the 6 companies Stoke Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
High 29.32 at 4:15 am ET, low 28.27 at 9:30 am ET.
Stoke Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
STOK (Stoke Therapeutics, Inc.) has 1 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.